SCHEMBL9976807

SCHEMBL9976807

COc1cc2c(cc1OC)-c1c(OC)c(OC)cc3c1C(C2)NCC3

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD1 P21728 4/20 0.76
HTR2C P28335 4/20 0.76
PTPRCAP Q14761 2/20 0.76
DRD2 P14416 4/20 0.74
KDM4E B2RXH2 6/20 0.73
ALDH1A1 P00352 6/20 0.73
HPGD P15428 3/20 0.73
HSD17B10 Q99714 2/20 0.73
MAPT P10636 3/20 0.58
POLB P06746 3/20 0.58
TDP2 O95551 2/20 0.58
CASP3 P42574 2/20 0.58
RAD52 P43351 2/20 0.58
SENP8 Q96LD8 2/20 0.58
SENP7 Q9BQF6 2/20 0.58
SENP6 Q9GZR1 2/20 0.58
CHRNB2 P17787 2/20 0.58
APOBEC3A P31941 2/20 0.58
CHRNA7 P36544 2/20 0.58
CHRNA4 P43681 2/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Laurotetanine SCHEMBL905125 0.92 DRD2 (0.74) DRD1HTR2CPTPRCAPDRD2KDM4E
Laurotetanine SCHEMBL905065 0.92 DRD2 (0.74) DRD1HTR2CPTPRCAPDRD2KDM4E
Laurotetanine SCHEMBL31300083 0.92 DRD2 (0.74) DRD1HTR2CPTPRCAPDRD2KDM4E
SCHEMBL14259791 0.90 DRD1 (0.71) DRD1HTR2CPTPRCAPDRD2KDM4E
SCHEMBL6689417 0.87 DRD1 (0.65) DRD1HTR2CPTPRCAPDRD2KDM4E
Nornuciferine SCHEMBL29787894 0.86 HTR2C (1.00) DRD1HTR2CPTPRCAPDRD2KDM4E
Nornuciferine SCHEMBL29501026 0.86 HTR2C (1.00) DRD1HTR2CPTPRCAPDRD2KDM4E
SCHEMBL9976810 0.86 DRD2 (0.63) DRD1HTR2CPTPRCAPDRD2KDM4E
SCHEMBL23949488 0.86 DRD2 (1.00) DRD1HTR2CPTPRCAPDRD2KDM4E
SCHEMBL563496 0.86 DRD2 (1.00) DRD1HTR2CPTPRCAPDRD2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140155609-A9 QUINOLINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DONG-A ST CO., LTD. (KR) 2014-06-05 US disclosed
US-20130296571-A1 QUINOLINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME DONG-A ST CO., LTD. (KR) 2013-11-07 US disclosed
US-8202995-B2 Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same STANDARD CHEM. & PHARM. CO., LTD. (TW) 2012-06-19 US disclosed
US-8202995-B2 Pharmaceutically acceptable salts of aporphine derivatives and carboxyl group-containing agents and methods for preparing the same STANDARD CHEM. & PHARM. CO., LTD. (TW) 2012-06-19 US disclosed
US-8093260-B2 Aporphine derivatives and pharmaceutical use thereof STANDARD CHEM. & PHARM. CO., LTD. (TW) 2012-01-10 US disclosed
US-8093260-B2 Aporphine derivatives and pharmaceutical use thereof STANDARD CHEM. & PHARM. CO., LTD. (TW) 2012-01-10 US disclosed
US-20090318488-A1 Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same STANDARD CHEM. & PHARM. CO., LTD. (TW) 2009-12-24 US disclosed
US-20090318488-A1 Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same STANDARD CHEM. & PHARM. CO., LTD. (TW) 2009-12-24 US disclosed
US-20090318489-A1 Aporphine compounds and pharmaceutical use thereof STANDARD CHEM. & PHARM. CO., LTD. (TW) 2009-12-24 US disclosed
US-20090318489-A1 Aporphine compounds and pharmaceutical use thereof STANDARD CHEM. & PHARM. CO., LTD. (TW) 2009-12-24 US disclosed
US-7294715-B2 Aporphine and oxoaporphine compounds and pharmaceutical use thereof LOTUS PHARMACEUTICAL CO., LTD. (TW) 2007-11-13 US disclosed
US-7294715-B2 Aporphine and oxoaporphine compounds and pharmaceutical use thereof LOTUS PHARMACEUTICAL CO., LTD. (TW) 2007-11-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318489-A1 Aporphine compounds and pharmaceutical use thereof IAPP, OPRL1, AGER DRD1 253/4885HTR2C 89/4885PTPRCAP 1642/4885
US-20090318488-A1 Pharmaceutically acceprable salts of aporphine compounds of carboxyl group-containing agents and methods for preparing the same IAPP, GPR119, AMY2A DRD1 1039/4885HTR2C 389/4885PTPRCAP 715/4885
US-20140155609-A9 QUINOLINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SLC10A2, VIP, SI DRD1 99/4885HTR2C 349/4885PTPRCAP 4580/4885
US-20130296571-A1 QUINOLINE DERIVATIVE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME SLC10A2, VIP, SI DRD1 99/4885HTR2C 349/4885PTPRCAP 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.